Mydecine Reports its 2023 Annual General Shareholders' Meeting Results VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the...

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental...

IBN (InvestorBrandNetwork) Announces Gamechangers LIVE Interview with Mydecine Innovations Group Inc. CEO Joshua Bartch NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that...